Profile data is unavailable for this security.
About the company
Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.
- Revenue in GBP (TTM)3.38m
- Net income in GBP-9.42m
- Incorporated2021
- Employees51.00
- LocationArecor Therapeutics PLCChesterford Research ParkLittle ChesterfordSAFFRON WALDEN CB10 1XLUnited KingdomGBR
- Phone+44 122 342 6060
- Websitehttps://arecor.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Groupe Berkem SA | 44.72m | 315.96k | 36.56m | 234.00 | 40.30 | -- | 9.56 | 0.8175 | 0.0593 | 0.0593 | 2.92 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 55.32 | -- | 0.7065 | -- | -- | 1.39 | -- | -- | 0.733 | -- | 123.42 | -- | -- | -- |
| Biosynex SA | 80.11m | -11.87m | 36.87m | 560.00 | -- | -- | -- | 0.4602 | -1.94 | -1.94 | -- | -- | -- | -- | -- | 248,141.30 | -- | 25.60 | -- | 33.90 | 25.22 | 51.82 | -13.15 | 20.26 | -- | -4.45 | -- | 14.72 | -48.61 | 45.12 | -84.99 | 118.26 | -- | -- |
| GeNeuro SA | 0.00 | -12.70m | 38.43m | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| Sequana Medical NV | 613.12k | -28.03m | 38.80m | 62.00 | -- | -- | -- | 63.28 | -1.22 | -1.22 | 0.0266 | -0.6905 | 0.0394 | 1.99 | 9.08 | 11,486.61 | -180.28 | -170.42 | -4,305.25 | -660.97 | -586.32 | -255.63 | -4,572.45 | -3,072.27 | 0.2055 | -8.92 | -- | -- | -22.82 | -7.10 | -5.85 | -- | 79.05 | -- |
| Bergenbio ASA | 26.06k | -14.02m | 39.42m | 18.00 | -- | 2.89 | -- | 1,512.69 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Enzymatica AB (publ) | 3.48m | -3.95m | 39.82m | 18.00 | -- | 6.45 | -- | 11.44 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Arecor Therapeutics PLC | 3.38m | -9.42m | 41.81m | 51.00 | -- | 3.16 | -- | 12.37 | -0.3108 | -0.3108 | 0.1114 | 0.4314 | 0.1805 | -- | 0.7516 | 66,254.90 | -50.32 | -- | -66.40 | -- | -- | -- | -278.81 | -- | 2.28 | -- | 0.0125 | -- | 107.51 | -- | -50.11 | -- | -- | -- |
| AbL Diagnostics SA | 9.63m | 1.04m | 42.45m | 19.00 | 5.10 | 7.35 | 162.52 | 4.41 | 0.5997 | 0.5997 | 5.58 | 0.4165 | 1.18 | -- | 5.21 | 588,990.50 | 12.67 | 8.99 | 26.09 | 10.77 | 35.76 | 38.29 | 10.75 | 31.17 | 1.28 | -- | 0.31 | 0.00 | -- | 67.89 | 328.77 | -- | -- | -- |
| Gentian Diagnostics ASA | 10.47m | -429.42k | 43.83m | 58.00 | -- | 3.93 | 166.29 | 4.19 | -0.3783 | -0.3783 | 9.22 | 9.82 | 0.7646 | 1.85 | 6.35 | 2,452,035.00 | -3.14 | -10.76 | -3.58 | -11.86 | 50.84 | 41.46 | -4.10 | -26.99 | 4.14 | -- | 0.0555 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| IRLAB Therapeutics AB | 417.93k | -13.09m | 43.84m | 37.00 | -- | 5.15 | -- | 104.89 | -3.43 | -3.43 | 0.1095 | 2.23 | 0.0227 | -- | 0.5137 | -- | -71.04 | -27.12 | -82.41 | -30.42 | -2,161.57 | -72.18 | -3,132.07 | -155.57 | -- | -- | 0.1923 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Oncopeptides AB | 2.59m | -18.34m | 45.12m | 57.00 | -- | 6.49 | -- | 17.41 | -1.96 | -1.96 | 0.2776 | 0.4474 | 0.1129 | -- | 1.44 | 617,894.80 | -79.88 | -141.28 | -101.04 | -200.49 | 103.06 | -- | -707.30 | -2,689.06 | -- | -- | 0.7065 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Poltreg SA | 280.87k | -2.72m | 45.88m | 23.00 | -- | 2.61 | -- | 163.34 | -2.91 | -2.91 | 0.300 | 18.77 | 0.0112 | 51.22 | 27.43 | 61,494.50 | -10.82 | -6.51 | -12.42 | -7.35 | -811.65 | -391.38 | -968.62 | -449.24 | 3.87 | -- | 0.0856 | -- | 40.04 | -- | -588.92 | -- | 214.26 | -- |
| Pangaea Oncology SA | 4.01m | -2.33m | 46.46m | 62.00 | -- | 2.65 | -- | 11.57 | -0.0898 | -0.0898 | 0.1557 | 0.6691 | 0.1601 | 3.86 | 1.23 | 76,449.51 | -9.46 | -11.40 | -10.90 | -14.62 | 38.92 | 79.42 | -59.10 | -57.87 | 2.57 | -- | 0.1054 | -- | -5.11 | 10.75 | -322.51 | -- | -33.46 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Lombard Odier Asset Management (Europe) Ltd.as of 04 Aug 2022 | 1.62m | 5.30% |
| Chelverton Asset Management Ltd.as of 30 Jun 2023 | 1.43m | 4.65% |
| Unicorn Asset Management Ltd.as of 04 Aug 2022 | 1.20m | 3.91% |
| Amati Global Investors Ltd.as of 04 Aug 2022 | 844.04k | 2.76% |
| Canaccord Genuity Wealth Ltd.as of 30 Sep 2023 | 631.69k | 2.06% |
| CRUX Asset Management Ltd.as of 30 Sep 2023 | 554.90k | 1.81% |
